IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.171
NA - Nord America 4.895
EU - Europa 3.517
SA - Sud America 2.396
AF - Africa 133
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.134
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.697
SG - Singapore 2.950
BR - Brasile 2.002
CN - Cina 1.885
HK - Hong Kong 1.288
SE - Svezia 1.035
IT - Italia 963
VN - Vietnam 594
RU - Federazione Russa 353
DE - Germania 338
AR - Argentina 173
FI - Finlandia 151
AT - Austria 115
GB - Regno Unito 113
NL - Olanda 112
EC - Ecuador 85
MX - Messico 85
IN - India 84
CA - Canada 78
IE - Irlanda 70
FR - Francia 59
BD - Bangladesh 57
PL - Polonia 57
ID - Indonesia 54
ZA - Sudafrica 50
PY - Paraguay 38
IQ - Iraq 35
JP - Giappone 35
CO - Colombia 32
ES - Italia 30
TR - Turchia 28
AE - Emirati Arabi Uniti 25
PK - Pakistan 25
MA - Marocco 22
UA - Ucraina 22
VE - Venezuela 22
CH - Svizzera 18
AU - Australia 15
CL - Cile 15
EG - Egitto 15
KE - Kenya 15
PE - Perù 15
UZ - Uzbekistan 15
LT - Lituania 13
TN - Tunisia 12
AZ - Azerbaigian 10
BE - Belgio 10
IL - Israele 9
IR - Iran 9
UY - Uruguay 9
JM - Giamaica 7
PA - Panama 7
SA - Arabia Saudita 7
GR - Grecia 6
KZ - Kazakistan 6
PH - Filippine 6
TW - Taiwan 6
AL - Albania 5
BO - Bolivia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
KR - Corea 5
KW - Kuwait 5
NO - Norvegia 5
RS - Serbia 5
BH - Bahrain 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
ET - Etiopia 4
LU - Lussemburgo 4
MV - Maldive 4
NP - Nepal 4
AO - Angola 3
BB - Barbados 3
BY - Bielorussia 3
LB - Libano 3
MY - Malesia 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
BW - Botswana 2
CR - Costa Rica 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
OM - Oman 2
SI - Slovenia 2
SV - El Salvador 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CY - Cipro 1
EE - Estonia 1
FJ - Figi 1
Totale 18.117
Salva come PNG Salva come JPEG
Città #
Dallas 2.071
Hong Kong 1.283
Singapore 1.208
Ashburn 493
Shanghai 469
Hefei 432
Lawrence 328
Princeton 328
Milan 262
Ho Chi Minh City 222
Beijing 217
São Paulo 163
New York 148
Moscow 145
Nuremberg 134
Hanoi 119
Rome 114
Los Angeles 108
Helsinki 88
Munich 75
Dublin 69
Boardman 64
Rio de Janeiro 54
Vienna 50
Warsaw 48
Guangzhou 42
Brasília 41
Belo Horizonte 39
Brooklyn 39
The Dalles 34
Turku 34
Curitiba 32
Guayaquil 31
Tokyo 31
Houston 29
Porto Alegre 29
Orem 28
Xi'an 28
Naples 27
Denver 26
Johannesburg 26
Lappeenranta 26
Montreal 26
Stockholm 26
Chennai 25
Santa Clara 25
Columbus 23
Haiphong 23
London 23
Mexico City 22
Quito 22
Dubai 21
Hangzhou 21
Seattle 21
Atlanta 20
Da Nang 20
Poplar 20
Ridgewood 20
Boston 19
Chicago 19
Ribeirão Preto 19
Thái Bình 19
Amsterdam 18
Salvador 18
Campinas 17
Manaus 17
Palermo 17
Pune 17
Frankfurt am Main 16
Guarulhos 16
Jakarta 15
Nairobi 15
Santo André 15
Ankara 14
Asunción 14
Cesano Boscone 14
Florianópolis 14
Manchester 14
Shenzhen 14
Tashkent 14
Tianjin 14
Toronto 14
San Francisco 13
Baghdad 12
Biên Hòa 12
Buenos Aires 12
Hải Dương 12
Phoenix 12
Querétaro 12
Sorocaba 12
São José dos Campos 12
Washington 12
Cairo 11
Cape Town 11
Caruaru 11
Goiânia 11
Kassel 11
Ninh Bình 11
Sydney 11
Turin 11
Totale 10.184
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 471
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 400
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 391
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 371
3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib 182
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) 166
Chronic lymphocytic leukaemia 103
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 97
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 97
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 96
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 93
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 84
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia 83
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 82
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 81
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 79
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 77
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 77
A new life for rituximab? 76
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 73
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 73
A woman and her canary: a tale of chlamydiae and lymphomas 71
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 69
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 68
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 67
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 67
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 67
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 67
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 67
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 66
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 66
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 66
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 65
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 64
Chronic lymphocytic leukemia 63
A frequent EcoRI polymorphism in the bcl-2 gene 63
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 63
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 63
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 62
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 62
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 62
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 61
Targeting B-cell anergy in chronic lymphocytic leukemia. 60
Monoclonal B-cell lymphocytosis: right track or red herring? 60
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 59
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 58
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 58
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 58
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 58
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 58
Supplementary Data from Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 57
TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics 57
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 57
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 56
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 56
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 56
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 56
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 55
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 55
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 53
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 53
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 53
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 53
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 52
Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia 52
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results 52
[Cellular and molecular mechanisms conditioning the accumulation of resting neoplastic cells in B-lymphocyte chronic lymphatic leukemia] 52
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 51
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 51
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 51
Monoclonal B lymphocytosis in the general population 51
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 51
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study 51
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA 51
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL) 51
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity? 50
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 50
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 50
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 50
Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact 50
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: Analysis within prospective clinical trials of the German CLL Study Group 50
Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system 50
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 49
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 49
Cytokines involved in the progression of multiple myeloma 49
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 49
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 49
Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset 8 49
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 49
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 48
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy 48
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 48
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 47
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 47
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 47
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 47
Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients 47
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia 47
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 47
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 47
Totale 7.636
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 25 3 0 1 0 0 0
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/20255.807 694 112 102 154 141 433 620 465 1.211 952 426 497
2025/20269.455 1.329 1.973 2.178 2.690 1.196 89 0 0 0 0 0 0
Totale 18.604